Biogen's latest treatment for multiple sclerosis helped repair damaged nerve tissue in a Phase II study, an incremental victory for a novel therapy that has a long way to go.
Biogen's latest evolution is more than just a nominal shift, according to its CEO, as the Big Biotech lops the Idec from its name and hopes to parlay its success in multiple sclerosis into some tough-to-treat diseases.
A group of investigators at the University of Chicago says they've found a drug that can guard myelin-producing cells, offering a possible new route to guarding against multiple sclerosis. And this is one therapy that has already been through the approval process.
Testing a theory that the molecule that transports proteins from the nucleus of a cell to the cytoplasm is altered in neurodegenerative diseases like multiple sclerosis, investigators say that they have successfully completed an animal study that tested drugs that could block the molecule and perhaps repair nerve cell damage that occurs in MS.
The former head of Johnson & Johnson's initiative to develop stratified drugs for Alzheimer's disease is trying to crowdfund the development of computer simulations of brain disorders. Magali Haas is seeking $299,900 for the project, which builds on a multiple sclerosis prediction model created by her nonprofit, Orion Bionetworks.
Alkermes' multiple sclerosis prodrug looks good in Phase I, has Biogen Idec's Tecfidera in its sights
Alkermes said the safety profile of its clinical-stage multiple sclerosis drug compares favorably to that of Biogen Idec's Tecfidera, citing the candidate's Phase I trial results on 104 patients.
The Google X lab that spawned smart contact lenses and self-driving cars is teaming up with Biogen Idec to unravel patient-to-patient variation in the progression of multiple sclerosis.
Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec will team up with Google to sift through a mountain of data on the topic, according to a report from Bloomberg.
Shares of Biogen Idec were buoyed this morning after the big biotech highlighted positive data from its mid-stage study of anti-LINGO-1, a closely watched drug that raises the potential for spurring remyelination--repairing the damage done by diseases like multiple sclerosis. But a careful second look at the results also underscores just how challenging this development program is for Biogen Idec.
Sanofi's Genzyme has found a silver lining to last winter's FDA snub of Lemtrada. For starters, Genzyme is fielding an extensive provider-and-patient support program, developed based on feedback from a range of stakeholders.